NCT00487773

Brief Summary

The purpose of the trial is to check if inhaled glucocorticosteroids (iGCS) have influence on bone condition (if iGCS increases risk of osteoporosis and bone fraction) in children with asthma.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
96

participants targeted

Target at P50-P75 for phase_4 asthma

Timeline
Completed

Started Sep 2007

Shorter than P25 for phase_4 asthma

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

June 18, 2007

Completed
1 day until next milestone

First Posted

Study publicly available on registry

June 19, 2007

Completed
2 months until next milestone

Study Start

First participant enrolled

September 1, 2007

Completed
1 year until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 1, 2008

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

September 1, 2008

Completed
Last Updated

April 13, 2010

Status Verified

April 1, 2010

Enrollment Period

1 year

First QC Date

June 18, 2007

Last Update Submit

April 12, 2010

Conditions

Keywords

asthmachildreninhaled glucocorticosteroidsbone metabolism

Outcome Measures

Primary Outcomes (1)

  • Markers of bone metabolism (from serum and urine)

    Baseline and 6 months

Secondary Outcomes (1)

  • Symptoms score (based on PAQLQ), spirometry

    baseline and 6 months

Study Arms (4)

1

ACTIVE COMPARATOR

budesonide

Drug: budesonide

2

ACTIVE COMPARATOR

D3 vitamin

Drug: D3 vitamin

3

ACTIVE COMPARATOR

montelukast sodium

Drug: montelukast sodium

4

ACTIVE COMPARATOR

salbutamol

Drug: salbutamol

Interventions

budesonide

1

D3 vitamin

2

montelukast sodium

3

salbutamol

4

Eligibility Criteria

Age5 Years - 18 Years
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64)

You may qualify if:

  • Allergic only to house dust mites
  • Never treated chronically (longer than at least 3 months) with anti-asthmatic drugs
  • Newly-diagnosed or non-treated asthma
  • Must be able to inhale drugs

You may not qualify if:

  • Other allergic diseases requiring treatment with glucocorticosteroids
  • Other chronic diseases
  • Asthma exacerbation
  • Pregnancy

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Department of Pediatrics and Allergy, Medical University of Lodz

Lodz, 93-513, Poland

Location

MeSH Terms

Conditions

Asthma

Interventions

BudesonideCholecalciferolmontelukastAlbuterol

Condition Hierarchy (Ancestors)

Bronchial DiseasesRespiratory Tract DiseasesLung Diseases, ObstructiveLung DiseasesRespiratory HypersensitivityHypersensitivity, ImmediateHypersensitivityImmune System Diseases

Intervention Hierarchy (Ancestors)

PregnenedionesPregnenesPregnanesSteroidsFused-Ring CompoundsPolycyclic CompoundsCholestenesCholestanesSterolsVitamin DSecosteroidsMembrane LipidsLipidsEthanolaminesAmino AlcoholsAlcoholsOrganic ChemicalsAminesPhenethylaminesEthylamines

Study Officials

  • Malgorzata Olszowiec-Chlebna, MD

    Department of Pediatrics and Allergy, Medical University of Lodz, Poland

    PRINCIPAL INVESTIGATOR
  • Iwona Stelmach, MD, PhD, Prof

    Department of Pediatrics and Allergy, Medical University of Lodz, Poland

    STUDY CHAIR

Study Design

Study Type
interventional
Phase
phase 4
Allocation
RANDOMIZED
Masking
TRIPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR
Intervention Model
PARALLEL
Sponsor Type
OTHER

Study Record Dates

First Submitted

June 18, 2007

First Posted

June 19, 2007

Study Start

September 1, 2007

Primary Completion

September 1, 2008

Study Completion

September 1, 2008

Last Updated

April 13, 2010

Record last verified: 2010-04

Locations